Amgen’s Otezla shows promise in psoriatic arthritis
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
Read More
Tag: Otezla
BMS’ deucravacitinib tops Otezla in two psoriasis studies
Deucravacitinib demonstrated superior skin clearance compared with Otezla
Read More
Amgen looks to expand access to Otezla in the US
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
Read More
Bristol Myers Squibb’s psoriasis med hits the mark in phase III
Deucravacitinib demonstrated superiority to placebo and Otezla in phase III
Read More
Amgen to acquire Celgene’s Otezla
The transaction is expected to close by the end of 2019.
Read More
Psoriasis patients to get NHS access to Otezla
Patients with severe plaque psoriasis living in England and Wales should now get access to Celgene’s Otezla on the NHS like their counterparts in Scotland, after cost regulators concluded that the drug is a cost-effective use of resources.
Read More
NICE backs Celgene’s Otezla for psoriatic arthritis
Celgene’s Otezla is being backed for routine use on the National Health Service in England and Wales to treat psoriatic arthritis.
Read More
NICE u-turn on Celgene’s Otezla for psoriasis
Patients with plaque psoriasis could be getting access to Celgene’s Otezla on the National Health Service in England and Wales after all, following a u-turn by cost regulators.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
